This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greene, C. M.
Right arrow Articles by Taggart, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greene, C. M.
Right arrow Articles by Taggart, C. C.

 Previous Article  |  Next Article 

Infection and Immunity, June 2004, p. 3684-3687, Vol. 72, No. 6
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.6.3684-3687.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Secretory Leucoprotease Inhibitor Impairs Toll-Like Receptor 2- and 4-Mediated Responses in Monocytic Cells

Catherine M. Greene,* Noel G. McElvaney, Shane J. O'Neill, and Clifford C. Taggart

Respiratory Research Division, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland

Received 16 July 2003/ Returned for modification 22 October 2003/ Accepted 12 February 2004

Secretory leucoprotease inhibitor (SLPI) is an anti-inflammatory antiprotease which can inhibit lipopolysaccharide-induced NF-{kappa}B activation. We examined its ability to inhibit NF-{kappa}B activation induced by lipoteichoic acid and investigated the effects of oxidation or complex formation with neutrophil elastase on SLPI's anti-inflammatory properties in U937 myelomonocytic cells and macrophages.


* Corresponding author. Mailing address: Respiratory Research Division, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland. Phone: 353-1-8093800. Fax: 353-1-8093808. E-mail: cmgreene{at}rcsi.ie.

Editor: S. H. E. Kaufmann


Infection and Immunity, June 2004, p. 3684-3687, Vol. 72, No. 6
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.6.3684-3687.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Geraghty, P., Greene, C. M., O'Mahony, M., O'Neill, S. J., Taggart, C. C., McElvaney, N. G. (2007). Secretory Leucocyte Protease Inhibitor Inhibits Interferon-{gamma}-induced Cathepsin S Expression. J. Biol. Chem. 282: 33389-33395 [Abstract] [Full Text]  
  • Samsom, J. N., van der Marel, A. P. J., van Berkel, L. A., van Helvoort, J. M. L. M., Simons-Oosterhuis, Y., Jansen, W., Greuter, M., Nelissen, R. L. H., Meeuwisse, C. M. L., Nieuwenhuis, E. E. S., Mebius, R. E., Kraal, G. (2007). Secretory Leukoprotease Inhibitor in Mucosal Lymph Node Dendritic Cells Regulates the Threshold for Mucosal Tolerance. J. Immunol. 179: 6588-6595 [Abstract] [Full Text]  
  • Butler, M. W., Robertson, I., Greene, C. M., O'Neill, S. J., Taggart, C. C., McElvaney, N. G. (2006). Elafin Prevents Lipopolysaccharide-induced AP-1 and NF-{kappa}B Activation via an Effect on the Ubiquitin-Proteasome Pathway. J. Biol. Chem. 281: 34730-34735 [Abstract] [Full Text]  
  • Katzenellenbogen, M., Pappo, O., Barash, H., Klopstock, N., Mizrahi, L., Olam, D., Jacob-Hirsch, J., Amariglio, N., Rechavi, G., Mitchell, L. A., Kohen, R., Domany, E., Galun, E., Goldenberg, D. (2006). Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the mdr2-knockout mice.. Cancer Res. 66: 4001-4010 [Abstract] [Full Text]  
  • Taggart, C. C., Cryan, S.-A., Weldon, S., Gibbons, A., Greene, C. M., Kelly, E., Low, T. B., O'Neill, S. J., McElvaney, N. G. (2005). Secretory leucoprotease inhibitor binds to NF-{kappa}B binding sites in monocytes and inhibits p65 binding. JEM 202: 1659-1668 [Abstract] [Full Text]